Xilio Therapeutics (XLO) Free Cash Flow Growth (1y) (2021 - 2026)
Xilio Therapeutics (XLO) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Xilio Therapeutics | 148.60 Mn | -1.70 Mn | - | -179.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -179.83% |
| Dec 31, 2025 | 85.75% |
| Sep 30, 2025 | -27.88% |
| Jun 30, 2025 | -173.21% |
| Mar 31, 2025 | 372.60% |
| Dec 31, 2024 | -5.48% |
| Sep 30, 2024 | -2.33% |
| Jun 30, 2024 | 218.13% |
| Mar 31, 2024 | 58.60% |
| Dec 31, 2023 | 20.48% |
| Sep 30, 2023 | 33.95% |
| Jun 30, 2023 | 3.63% |
| Mar 31, 2023 | -20.54% |
| Dec 31, 2022 | 4.36% |
| Sep 30, 2022 | -0.42% |
| Jun 30, 2022 | 14.81% |
| Mar 31, 2022 | 7.92% |
| Dec 31, 2021 | -37.78% |